Novo Nordisk on Wednesday announced that it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous expectation to file towards end-2025.
“In order to secure supply chain readiness, Novo Nordisk now expects to file for the first regulatory approval of CagriSema during the first quarter of 2026,” The Danish company said in its full-year.
The Danish company said it expects sales growth in local currencies to range between 16% and 24%, less than the 26% growth seen in 2024. That compares with analysts expectations of just under 20%. According to news agency Reuters, the company is also grappling with competition from Eli Lilly.
It said fourth-quarter operating profit jumped 37% to 36.7 billion Danish crowns ($5.12 billion), better than the 33.6 billion forecast by analysts in a company poll. It predicted operating profit for 2025 to climb between 19% and 27%, compared to growth of 26% last year.
During the fourth quarter, sales of Wegovy more than doubled to 19.9 billion crowns from 9.6 billion a year ago, in line with expectations and more than the 17.3 billion crowns achieved in the third quarter.
(With inputs from Reuters)
